How Heart Specialists Benefit from Medicare’s TAVR Restrictions

Medicare’s 14-year-old restrictions on a lifesaving heart procedure may finally be lifted by June 15—but the policy has quietly benefited the very specialists who perform it. The Coverage with Evidence Development (CED) requirement for Transcatheter Aortic Valve Replacement (TAVR) has limited patient access since 2011, forcing Medicare beneficiaries to enroll in registries and studies that many cardiologists say enriched their field at the cost of timely care. This policy could change within days, sparking debate over who wins and who loses when government oversight ends. TAVR is a minimally invasive alternative to open-heart surgery for aortic stenosis, a condition that thickens the heart’s main valve and can be fatal without treatment. The FDA approved the first TAVR device in 2011, but the Centers for Medicare & Medicaid Services (CMS) immediately imposed a CED requirement, mandating that all Medicare patients receive the procedure only as part of an approved clinical study or registry. For 14 years, that restriction remained in place, even as TAVR technology improved and evidence of its safety and effectiveness grew. Advocates argue the CED was intended to gather long-term outcomes data, but critics say it became an unnecessary barrier—especially for elderly patients who could not travel to participating centers or meet enrollment criteria. The central finding of the Forbes report is that heart specialists and hospitals have benefited from the restrictions in multiple ways: participation in registries provided a steady stream of data for research grants and publications, while limiting patient volume allowed high-volume centers to maintain premium pricing and procedure reimbursements without competition. Named experts in the piece suggest that some cardiologists have publicly supported keeping the CED because it ensures their institutions remain the exclusive providers of TAVR under Medicare. The deadline of June 15 appears to be a CMS decision date on whether to drop the CED requirement entirely. The proposed rule, first published in the Federal Register earlier this year, would allow TAVR to be covered under standard Medicare criteria, potentially opening the procedure to thousands more patients each year. The implications are significant: if the CED is removed, smaller hospitals and rural centers may begin offering TAVR, increasing patient access and driving down costs through competition. However, high-volume academic hospitals—the very ones that have dominated TAVR under the CED—could lose market share and research data pipelines. What happens next will set a precedent for how Medicare handles CED requirements for other emerging technologies. Patient advocacy groups are closely watching the June 15 date, while professional societies like the American College of Cardiology and the Society of Thoracic Surgeons have offered mixed statements—some welcoming expanded access, others warning about loss of real-world data collection. The decision could be announced as soon as June 15, 2026. If the CED is lifted, Medicare beneficiaries with aortic stenosis may no longer need to navigate a maze of restrictive studies to receive a procedure that has become the standard of care. The long-running debate over TAVR Medicare restrictions may finally reach a turning point.